(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Sanofi Pasteur today announced the start of the first clinical trial of an H7N1 influenza vaccine, intended to guard against the threat of a pandemic caused by H7 strains of avian influenza.
Current concern about a flu pandemic focuses mainly on the H5N1 avian flu virus, which has infected at least 247 people and killed 144. But H7 avian flu viruses have caused a number of mild illness cases and one death in the past 3 years.
(CIDRAP News) Clinical trials of a vaccine designed to keep the H5N1 avian influenza virus from sparking a human flu pandemic will begin early in 2005, the head of the National Institute of Allergy and Infectious Diseases (NIAID) said this week.